Influence of combination of Rosiglitazone wtih Metformin/Glimepiride onErythropoeitic and germinal cell damages in male diabetic rats

Abstract

Monotherapy of oral hypoglycemics in chronic diabetes rarely maintain the optimum glycemic control and is considered themajor cause for late onset complications. In this study combination of rosiglitazone (Rosi-0.2 mg/kg) with metformin (Met-50 mg/kg) or glimepiride (Gmp – 0.2 mg/kg) orally once daily for 4 weeks was tested against type 2 diabetes mellitus(T2DM) induced by nicotinamide (NA-230 mg/kg, i.p) and streptozotocin (STZ-65 mg/kg, i.p) in male Wistar rats. Resultsindicated that experimental T2DM significantly (P<0.001) increased micronucleated erythrocytes, sperm shape abnormalityand decreased the P/N (polychromatic: normochromatic erythrocytes) ratio, sperm count and weight of testis along with anincrease in the oxidative stress and blood glucose level compared to normal animals. Administration of Rosi+Metsignificantly (P<0.05) reduced the population of micronucleated erythrocytes, sperm shape abnormality, hyperglycemiabesides improving the sperm count and antioxidant defense system in the diabetic rats. However, Rosi+Gmp activity wasrestricted to only the antidiabetic effect. The observations suggest that Rosi+Met reduced the somatic and germinal celldamages in the diabetic animals owing to the antioxidant property.